Aberdeen Group plc Boosts Position in Royalty Pharma PLC $RPRX

by · The Markets Daily

Aberdeen Group plc increased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 7.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 228,746 shares of the biopharmaceutical company’s stock after acquiring an additional 14,886 shares during the quarter. Aberdeen Group plc’s holdings in Royalty Pharma were worth $8,212,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in RPRX. USA Financial Formulas purchased a new stake in Royalty Pharma during the second quarter worth approximately $32,000. Summit Securities Group LLC purchased a new stake in Royalty Pharma during the first quarter worth approximately $36,000. WPG Advisers LLC purchased a new stake in Royalty Pharma during the first quarter worth approximately $39,000. Allworth Financial LP lifted its stake in Royalty Pharma by 41.6% during the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 452 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in Royalty Pharma by 42.1% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 402 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RPRX. Wall Street Zen cut Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Saturday, September 13th. Citigroup lifted their price target on Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, July 22nd. Weiss Ratings raised Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Morgan Stanley cut their price target on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Finally, The Goldman Sachs Group began coverage on Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $46.00.

Get Our Latest Research Report on RPRX

Royalty Pharma Trading Up 0.4%

Shares of RPRX stock opened at $36.34 on Friday. The business’s 50 day moving average is $36.06 and its two-hundred day moving average is $34.76. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $38.00. The company has a market capitalization of $21.19 billion, a P/E ratio of 21.01, a price-to-earnings-growth ratio of 1.99 and a beta of 0.60. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.74.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%.The company had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. Equities analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Company Profile

(Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Read More

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).